Australian healthtech had a strong start to 2026. Preliminary data from Cut Through Venture shows the sector raised approximately $620 million across 22 deals in the first two months of the year—putting it on track to exceed 2025’s total of $1.4 billion if the pace holds.

The composition of funding has shifted notably. AI-powered diagnostics and remote patient monitoring together account for 58% of capital raised, up from 34% in the same period last year. Telehealth platforms, which dominated healthtech investment during 2020-2022, have dropped to single-digit percentages as the sector consolidates around a handful of established players.

Where Capital Is Concentrating

Diagnostic AI is the headline story. Melbourne-based Harrison.ai, already one of Australia’s best-funded healthtech companies, raised a $160 million Series C in January to expand its radiology and pathology AI tools into Southeast Asian markets. The round was led by Horizons Ventures with participation from Blackbird and Skip Capital.

Harrison.ai’s products are now used in over 400 radiology practices across Australia, processing an estimated 2.3 million scans annually. The clinical evidence base is maturing—peer-reviewed studies published in the Medical Journal of Australia show their chest X-ray AI matching radiologist accuracy on specific pathologies, though the company is careful to position the technology as assistive rather than autonomous.

Remote patient monitoring (RPM) attracted $180 million across five deals. The largest was Sydney-based Vitalic Health’s $85 million Series B for its chronic disease monitoring platform, which integrates wearable sensor data with clinical decision-support tools. Vitalic currently monitors 42,000 patients with diabetes, heart failure, and COPD across 15 Primary Health Networks.

The RPM category benefits from a clear economic argument. Hospital avoidance is the most direct path to cost reduction in Australia’s health system, and RPM programs demonstrate measurable reductions in emergency presentations and hospital readmissions. The CSIRO’s Digital Health CRC published data in December showing that RPM programs for chronic heart failure patients reduced hospital readmissions by 31% over 12 months.

Mental health technology raised $95 million, concentrated in two significant rounds. This sub-sector has matured beyond simple therapy-matching platforms into clinical-grade tools—AI-assisted psychological assessments, digital cognitive behavioural therapy programs with clinician oversight, and crisis prediction models.

The Regulatory Advantage

Australia’s regulatory framework for health technology, administered by the Therapeutic Goods Administration (TGA), is emerging as a competitive strength rather than just a compliance burden.

The TGA’s SaMD (Software as a Medical Device) classification system, updated in mid-2025, provides relatively clear pathways for AI-based diagnostic tools. Companies know what clinical evidence is required, what validation standards apply, and roughly how long approval takes. This predictability makes Australian healthtech companies more investable.

Contrast this with the US, where the FDA’s approach to AI-based medical devices remains in flux. The agency has approved over 900 AI/ML-enabled devices, but the regulatory pathway varies considerably by device type, and post-market monitoring requirements keep evolving. Australian companies that achieve TGA approval find it easier to navigate subsequent FDA submissions because TGA standards are internationally respected.

The Tech Council of Australia’s 2025 health technology report noted that regulatory clarity is one of the top three factors international investors cite when evaluating Australian healthtech deals. The others are clinical trial infrastructure and access to high-quality public health data through systems like My Health Record.

Commercialisation Remains the Hard Part

Raising capital is one thing. Getting paid for technology is another. Australian healthtech companies face persistent challenges in converting clinical evidence into recurring revenue.

The Medicare Benefits Schedule (MBS) is the dominant funding mechanism for healthcare in Australia, and it wasn’t designed for digital health. Adding new MBS item numbers for AI-assisted diagnostics or remote monitoring services requires lengthy application processes through the Medical Services Advisory Committee (MSAC). Companies report 18-24 month timelines from application to funding decision.

Some companies bypass MBS entirely by selling directly to hospitals, private health insurers, or primary care networks on a subscription basis. This approach works but limits addressable market size and creates fragmented revenue streams.

The $400 million Strengthening Medicare Fund, announced in the 2025-26 budget, includes specific allocations for digital health integration. How that money flows will shape commercialisation pathways for dozens of healthtech companies. Early indications suggest funding will prioritise technologies that reduce pressure on general practice and emergency departments—which aligns well with RPM and diagnostic AI.

International Expansion Patterns

Australian healthtech companies are increasingly targeting Southeast Asia for growth, and the patterns are becoming clearer.

Indonesia, with 275 million people and a healthcare system rapidly digitising, is the most common first market. Singapore serves as a regional headquarters and regulatory beachhead—TGA approval facilitates Singapore’s Health Sciences Authority (HSA) approval, which in turn provides access to broader ASEAN markets.

Harrison.ai’s expansion strategy is instructive. They established a Singapore entity in 2024, obtained HSA approval for their radiology AI, and are now deploying in Indonesian hospital networks through partnerships with local health system operators. This hub-and-spoke model—Australian R&D, Singapore regional base, deployment into Southeast Asian markets—is becoming the standard playbook.

India presents a larger opportunity but greater complexity. Regulatory requirements vary by state, price sensitivity is extreme, and competition from domestic companies is fierce. Australian healthtech companies that succeed in India typically do so through joint ventures with established Indian healthcare companies rather than direct market entry.

What to Watch

The healthtech sector’s trajectory over the next 12 months depends on several variables. MBS reform for digital health will determine whether Australian companies can build sustainable domestic revenue. TGA processing times for AI-based devices—currently running at 8-12 months—will affect how quickly new products reach market.

The workforce question is also pressing. Australia needs clinicians who understand technology and technologists who understand clinical workflows. The intersection of those skill sets is narrow, and companies that can attract and retain people with both capabilities will have a significant advantage.

Australian healthtech has the capital, the clinical evidence, and the regulatory framework to build globally significant companies. The question is whether commercialisation pathways can mature fast enough to match the ambition.